Research
Print page Print page
Switch language
Rigshospitalet - a part of Copenhagen University Hospital
Published

Effect of levothyroxine on live birth rate in euthyroid women with recurrent miscarriage and TPO antibodies (T4-LIFE study)

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Thyroid peroxidase antibodies and prospective live birth rate: A cohort study of women with recurrent pregnancy loss

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Gestational diabetes is associated with change in the gut microbiota composition in third trimester of pregnancy and postpartum

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Recurrence rates after abdominal and vaginal cerclages in women with cervical insufficiency: a validated cohort study

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Gentagne Graviditetstab

    Research output: Contribution to journalJournal articleResearchpeer-review

  • R Vissenberg
  • M M van Dijk
  • E Fliers
  • J A M van der Post
  • M van Wely
  • K W M Bloemenkamp
  • A Hoek
  • W K Kuchenbecker
  • H R Verhoeve
  • H C J Scheepers
  • S Rombout-de Weerd
  • C Koks
  • J J Zwart
  • F Broekmans
  • W Verpoest
  • O Christiansen
  • M Post
  • D N M Papatsonis
  • M F G Verberg
  • J Sikkema
  • B W Mol
  • P H Bisschop
  • M Goddijn
View graph of relations

BACKGROUND: Thyroid peroxidase antibodies (TPO-Ab) in euthyroid women are associated with recurrent miscarriage (RM) and other pregnancy complications such as preterm birth. It is unclear if treatment with levothyroxine improves pregnancy outcome. Aim To determine the effect of levothyroxine administration on live birth rate in euthyroid TPO-Ab positive women with recurrent miscarriage.

METHODS: /Design We will perform a multicenter, placebo controlled randomized trial in euthyroid women with recurrent miscarriage and TPO-Ab. Recurrent miscarriage is defined as two or more miscarriages before the 20th week of gestation. The primary outcome is live birth, defined as the birth of a living fetus beyond 24weeks of gestation. Secondary outcomes are ongoing pregnancy at 12weeks, miscarriage, preterm birth, (serious) adverse events, time to pregnancy and survival at 28days of neonatal life. The analysis will be performed according to the intention to treat principle. We need to randomize 240 women (120 per group) to demonstrate an improvement in live birth rate from 55% in the placebo group to 75% in the levothyroxine treatment group. This trial is a registered trial (NTR 3364, March 2012). Here we discuss the rationale and design of the T4-LIFE study, an international multi-center randomized, double blind placebo controlled, clinical trial aimed to assess the effectiveness of levothyroxine in women with recurrent miscarriage and TPO-Ab.

Original languageEnglish
JournalContemporary Clinical Trials
Volume44
Pages (from-to)134–138
ISSN1551-7144
DOIs
Publication statusPublished - 5 Aug 2015

ID: 46177877